Immunic director granted 25,370 stock options

IMMUNIC, INC. director Tamar D. Howson received a grant of stock options covering 25,370 shares of common stock.

Rhea-AI Filing Summary

IMMUNIC, INC. director Tamar D. Howson received a grant of stock options covering 25,370 shares of common stock. The options have an exercise price of $10.90 per share, are fully vested as of March 27, 2026, and expire on March 27, 2036. The grant was conditionally approved by the Board on March 27, 2026, subject to stockholder approval of an amendment to the company’s 2019 Omnibus Equity Incentive Plan, which was obtained at the 2026 Annual Meeting of Stockholders held on June 29, 2026.

Insider Trade Summary

Grant/Award: 25,370 shares

Grant/Award 1 txn

Insider HOWSON TAMAR D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	25,370	$0.00	$0.00

Holdings After Transaction: Stock Option — 25,370 contracts (Direct)

Footnotes (2)

1. F1. Represents options to purchase shares of common stock conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026.
2. F2. The option is fully vested as of March 27, 2026.

Key Figures

Option grant size: 25,370 options Exercise price: $10.90 per share Expiration date: March 27, 2036 +4 more

7 metrics

Option grant size 25,370 options Stock options covering 25,370 shares of common stock

Exercise price $10.90 per share Exercise price for the granted stock options

Expiration date March 27, 2036 Options expire on March 27, 2036

Vesting status date Fully vested as of March 27, 2026 Footnote states the option is fully vested as of this date

Post-transaction holdings 25,370 options Total stock options held following the transaction

Board conditional approval date March 27, 2026 Options conditionally approved by the Board on this date

Stockholder approval date June 29, 2026 Approval obtained at 2026 Annual Meeting of Stockholders

Key Terms

Stock Option, 2019 Omnibus Equity Incentive Plan, Annual Meeting of Stockholders, Grant, award, or other acquisition

4 terms

Stock Option financial

"Represents options to purchase shares of common stock conditionally approved by the Board of Directors"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

2019 Omnibus Equity Incentive Plan financial

"subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended"

Annual Meeting of Stockholders regulatory

"approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026"

Grant, award, or other acquisition financial

"transaction code description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Immunic (IMUX) report for Tamar D. Howson?

Immunic reported that director Tamar D. Howson received a grant of stock options for 25,370 shares of common stock. These options were awarded as a compensation-related grant rather than an open-market purchase or sale of existing Immunic shares.

What is the exercise price and share amount of Tamar D. Howson’s Immunic stock options?

Tamar D. Howson’s stock option grant covers 25,370 shares of Immunic common stock at an exercise price of $10.90 per share. This means she can buy up to 25,370 shares at $10.90 if she chooses to exercise the options before expiration.

When do Tamar D. Howson’s Immunic stock options vest and expire?

The stock options granted to Tamar D. Howson are fully vested as of March 27, 2026. The options carry an expiration date of March 27, 2036, giving a ten-year window during which they may be exercised at the stated exercise price.

What approvals were required for Tamar D. Howson’s Immunic stock option grant?

The options were conditionally approved by Immunic’s Board of Directors on March 27, 2026, subject to stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan. Stockholders provided this approval at Immunic’s 2026 Annual Meeting held on June 29, 2026.

How many Immunic stock options does Tamar D. Howson hold after this grant?

Following this grant, Tamar D. Howson holds 25,370 stock options directly. Each option is exercisable for one share of Immunic common stock, aligning the total option count with 25,370 underlying common shares if fully exercised.

Is Tamar D. Howson’s Immunic option grant an open-market trade or compensation award?

The filing describes the transaction as a grant or award acquisition of derivative securities, coded as an option grant. It is a compensation-related award, not an open-market purchase or sale of Immunic common stock on an exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:33 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HOWSON TAMAR D

(Last) (First) (Middle)

1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$10.9	06/29/2026		A		25,370(1)		(2)	03/27/2036	Common Stock	25,370	$0.00	25,370	D

Explanation of Responses:

1. Represents options to purchase shares of common stock conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026.

2. The option is fully vested as of March 27, 2026.

	/s/ Tamar Howson	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)